MD Anderson Cancer Center
Houston, United States
Dr. Fueyo is professor of Neuro-Oncology - Research and director of Neuro-Oncology Experimental Research at The University of Texas MD Anderson Cancer Center. He holds a dual appointment as a faculty member in Neurosurgery at MD Anderson as well as at the MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences. Dr. Fueyo completed his medical degree and a residency in Neurology at the Autonomous University of Barcelona, Spain. After completing a fellowship in Experimental Neuro-Oncology at MD Anderson, he was promoted to a faculty position.
As principal investigator of studies funded by the NIH, the Department of Defense, the Cancer Prevention and Research Institute of Texas, Dr. Fueyo is developing novel virotherapy strategies for fighting gliomas. He also is a leader of the prestigious NIH Specialized Program of Research Excellence (SPORE) in brain cancer at his institution. The committed decade-long research of Dr. Fueyo and his team led to their engineering of the oncolytic adenovirus Delta-24, which is showing great promise as a potential therapy for patients with glioblastoma. Dr. Fueyo’s current focus is to improve the anticancer effect of oncolytic adenoviruses — by modifying Delta-24 and also using different gene delivery methods — and to translate those findings to the clinic.
The Delta-24 research of Dr. Fueyo and his team was recognized by MD Anderson through the Waun Ki Hong Award for Excellence in Team Science. In addition, he received the Peter A. Steck Memorial Award presented by the Pediatric Brain Tumor Foundation. In 2018, he was included in the Spanish Selection of Science by the Spanish National Research Council. Dr. Fueyo serves on many scientific sections of NIH, DOD, and several national and international scientific meetings. He has published more than 250 peer‑reviewed and invited articles, abstracts, book chapters, letters to the editor and editorials.